| Teresita E Alejandro, REGISTERED NURSE | |
|
241 W Passaic St Apt 2a, Rochelle Park, NJ 07662-3115 | |
| (201) 214-6236 | |
| Not Available |
| Full Name | Teresita E Alejandro |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse |
| Location | 241 W Passaic St Apt 2a, Rochelle Park, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184966350 | NPI | - | NPPES |
| 536542-1 | Other | NY | NEW YORK EDUCATION DEPARTMENT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 536452-1 (New York) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Teresita E Alejandro, REGISTERED NURSE 241 W Passaic St Apt 2a, Rochelle Park, NJ 07662-3115 Ph: (201) 214-6236 | Teresita E Alejandro, REGISTERED NURSE 241 W Passaic St Apt 2a, Rochelle Park, NJ 07662-3115 Ph: (201) 214-6236 |
News Archive
A new report identifies the enormous global impact of preterm birth and stillbirth—and what can be done to decrease it. Globally, an estimated 13 million babies are born preterm each year. Newborn deaths now account for more than 42 percent of mortality in children under the age of five, a rise from 37 percent in the year 2000. Additionally, an estimated 3.2 million are stillborn each year, and many of these losses are linked to maternal deaths.
Researchers within the Observational Health Data Services and Informatics (OHDSI) community were recently awarded a $10 million contract from the U.S. Food and Drug Administration (FDA) to provide support to the Biologics Effectiveness and Safety (BEST) program, which was launched by the FDA Center for Biologics Evaluation and Research (CBER) in 2017.
Eschmann Technologies has launched a revolutionary air disinfection system developed by Novaerus to help protect dentists against the spread of airborne viruses such as COVID-19.
As fall begins, so do youth sports like football, baseball, softball and soccer — all of which can result in sport-related injuries to the mouth.
Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial collaboration agreement with Merck, through a Merck subsidiary, to evaluate the safety and efficacy of Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, and Merck's investigational anti-PD-1 immunotherapy, MK-3475, in a Phase I/II study in previously treated metastatic and recurrent non-small cell lung cancer (NSCLC), and other advanced or metastatic cancers.
› Verified 5 days ago
Ms. Diane Stoller, R.N. Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 336 W Passaic St, 2nd Fl, Rochelle Park, NJ 07662 Phone: 201-845-7030 Fax: 201-845-0899 | |
Miarose Reyes, RN/IBCLC Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 54 Forest Pl, Rochelle Park, NJ 07662 Phone: 201-658-4282 | |
Muhiba Begum, PMHNP-BC Registered Nurse Medicare: Medicare Enrolled Practice Location: 39 Marinus St, Rochelle Park, NJ 07662 Phone: 862-686-0421 |